<?xml version='1.0' encoding='utf-8'?>
<document id="31199498"><sentence text="Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations." /><sentence text="We predicted the drug-drug interaction (DDI) potential of siponimod in presence of cytochrome P450 (CYP)2C9/CYP3A4 inhibitors/inducers in subjects with different CYP2C9 genotypes by physiologically-based pharmacokinetic (PK) modeling" /><sentence text=" The model was established using in vitro and clinical PK data and verified by adequately predicting siponimod PK when coadministered with rifampin"><entity charOffset="139-147" id="DDI-PubMed.31199498.s3.e0" text="rifampin" /></sentence><sentence text=" With strong and moderate CYP3A4 inhibitors, an increased DDI risk for siponimod was predicted for CYP2C9*3/*3 genotype vs" /><sentence text=" other genotypes area under the curve ratio (AUCR): 3" /><sentence text="03-4" /><sentence text="20 vs" /><sentence text=" ≤ 1" /><sentence text="49 for strong; 2" /><sentence text="42 vs" /><sentence text=" 1" /><sentence text="14-1" /><sentence text="30 for moderate" /><sentence text=" AUCRs increased with moderate (2" /><sentence text="13-2" /><sentence text="49) and weak (1" /><sentence text="12-1" /><sentence text="42) CYP3A4/CYP2C9 inhibitors to the same extent for all genotypes" /><sentence text=" With strong CYP3A4/moderate CYP2C9 inducers and moderate CYP3A4 inducers, predicted AUCRs were 0" /><sentence text="21-0" /><sentence text="32 and 0" /><sentence text="35-0" /><sentence text="71, respectively" /><sentence text=" This complementary analysis to the clinical PK-DDI studies confirmed the relevant influence of CYP2C9 polymorphism on the DDI behavior of siponimod and represented the basis for the DDI labeling recommendations" /><sentence text="" /></document>